Lance Armstrong, Endurance, and the Ethics of Celebrity Rx Disclosure

What Does "Endurance" Mean as a Drug Category?

"Endurance" as a colloquial label covers any compound that increases oxygen delivery, delays fatigue, or accelerates muscular recovery. Clinically, this includes erythropoiesis-stimulating agents (ESAs) such as epoetin alfa, anabolic androgens including testosterone, human growth hormone (HGH), and, more recently, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitors. Each of these carries an FDA-regulated indication for specific medical conditions, yet each has a documented history of off-label misuse in athletic contexts.

Erythropoiesis-Stimulating Agents

Epoetin alfa (brand name Epogen, Procrit) is FDA-approved for anemia associated with chronic kidney disease, chemotherapy, and HIV therapy [1]. By stimulating red blood cell production, it raises hematocrit and hemoglobin, increasing aerobic capacity. A 2009 Cochrane review examining ESA safety in oncology patients (N=13,611 across 53 trials) found that ESA use was associated with a relative risk of thromboembolic events of 1.67 (95% CI 1.35 to 2.06) compared with control [2]. In healthy athletes using supraphysiologic doses without medical supervision, that thrombotic risk is amplified further.

Testosterone and Androgen Therapy

Testosterone is FDA-approved for hypogonadism in men with confirmed low serum levels [3]. The Endocrine Society's 2018 clinical practice guideline recommends against prescribing testosterone to men with normal serum concentrations, stating: "We recommend against testosterone therapy in men who do not have a clinical syndrome consistent with testosterone deficiency" [4]. Off-label use in athletes seeks to accelerate recovery, increase lean mass, and raise red blood cell mass through androgen-driven erythropoiesis.

Human Growth Hormone

HGH (somatropin) is FDA-approved for growth hormone deficiency, short stature, and wasting syndromes [5]. Meta-analyses of HGH supplementation in healthy adults show modest increases in lean body mass but no consistent strength or endurance benefit [6]. The FDA explicitly warns that distributing HGH for anti-aging or athletic purposes is illegal under the Food, Drug, and Cosmetic Act [5].

Lance Armstrong's Documented Substance Use: The Clinical Record

Armstrong's doping program is not rumor or inference. The United States Anti-Doping Agency's 2012 Reasoned Decision (1,000+ pages, 26 witnesses) documented systematic use of EPO, testosterone, HGH, corticosteroids, and autologous blood transfusions across his 1998 to 2005 Tour de France period [7]. Armstrong confirmed the program in a January 2013 televised interview. The clinical details matter because they illustrate exactly which physiological systems were being manipulated.

EPO Use: Confirmed Mechanism and Dose Range

Armstrong confirmed EPO use during the 1999 to 2005 period. EPO at doses used in athletic doping (typically 20 to 50 IU/kg subcutaneously three times per week) raises hematocrit from a typical 42 to 46 percent range up to 49 to 51 percent, the upper limit policed by the UCI's "50% rule" from 1997 onward [8]. A 1-percent increase in VO2 max translates to roughly a 0.4-percent improvement in time-trial performance, according to exercise physiology modeling published in the Journal of Applied Physiology [9].

Testosterone: Medical vs. Athletic Use

Testosterone was used in Armstrong's program as a recovery agent, applied transdermally after stages. Normal male serum testosterone ranges from 300 to 1,000 ng/dL according to the Endocrine Society [4]. USADA testimony described testosterone concentrations in Armstrong's samples that far exceeded the 4:1 testosterone-to-epitestosterone (T/E) ratio threshold then used by WADA [7]. The T/E ratio test was eventually supplemented by the Athlete Biological Passport and carbon isotope ratio testing, which are now considered more reliable [8].

Corticosteroids and Therapeutic Use Exemptions

Armstrong held therapeutic use exemptions (TUEs) for corticosteroids during parts of his career, citing saddle sores. Corticosteroids are potent anti-inflammatory agents that also mobilize free fatty acids, sparing glycogen during prolonged effort. The WADA prohibited list classifies glucocorticoids as banned in-competition only when administered by injection, oral, or rectal routes [8]. TUEs exist for legitimate medical need, but their misuse as performance tools is a well-documented regulatory problem the World Anti-Doping Agency has acknowledged in successive code revisions.

The Ethics of Celebrity Medication Disclosure

Armstrong's story is useful precisely because it is so thoroughly documented. It gives clinicians and patients a concrete case for examining how celebrity health claims shape public behavior.

Why Celebrity Disclosure Carries Downstream Risk

When a public figure with millions of followers states that a specific compound improved their health, performance, or body composition, a predictable pattern follows. Demand for that compound rises. Online pharmacies and gray-market suppliers see volume increases. Patients ask their physicians for off-label prescriptions. Some obtain compounds without any medical supervision at all.

A 2023 analysis in JAMA Internal Medicine found that 37 percent of surveyed adults reported that celebrity health endorsements influenced at least one health-related decision in the prior year [10]. The influence is larger for social media endorsements than for traditional advertising, and larger still when the celebrity is perceived as having direct personal experience with the product.

The Informed-Consent Parallel

Physicians are required by professional and legal standards to give patients material information about treatments, including risks. Celebrities operate under no such obligation. Yet the psychological impact on health decision-making may be comparable. When a seven-time Tour de France champion (subsequently stripped) describes a recovery protocol, the implicit message is that it worked at the highest level of human performance. The risks are rarely part of that narrative.

The FDA's Bad Ad Program, which targets misleading prescription drug promotion, applies to healthcare providers but not to celebrities speaking about personal experience [11]. That regulatory gap is a real and continuing problem.

Specific Harms Documented in the Literature

The clinical literature documents concrete harms from the kind of unsupervised use that celebrity endorsement can trigger:

• EPO misuse has been associated with sudden cardiac death in young athletes. A widely cited but methodologically limited estimate suggested 18 Dutch and Belgian cyclists died between 1987 and 1990, coinciding with the early EPO era, though causation was not proven [12].
• Testosterone misuse in non-hypogonadal men suppresses endogenous production via hypothalamic-pituitary axis feedback, causing hypogonadism that can persist for 12 to 24 months after cessation, according to a 2014 review in Fertility and Sterility [13].
• Exogenous HGH use in adults without growth hormone deficiency raises IGF-1 above normal ranges, and sustained IGF-1 elevation has been associated with increased colorectal and prostate cancer risk in prospective cohort data [14].

A Clinical Framework for Evaluating Celebrity Rx Claims

Clinicians and patients evaluating any celebrity medication disclosure can apply four questions:

1. Is the compound FDA-approved for the claimed use, or is this off-label?
2. What is the documented adverse-event profile in supervised clinical trials?
3. Is the celebrity's physiological context (elite athlete, cancer survivor, specific diagnosis) transferable to the general patient?
4. Has the disclosure been reviewed or countersigned by a named, licensed clinician?

Armstrong himself has spoken about his cancer treatment (testicular cancer diagnosed in 1996) and the physiological demands of elite cycling, but public statements about specific current medication regimens, if any exist, have not been medically reviewed for general-audience safety guidance. Any inference about his current use of any compound labeled "Endurance" or otherwise should be treated as exactly that: inference, not clinical guidance.

What Legitimate Endurance Medicine Looks Like in 2025

The same physiological goals that drove Armstrong's doping program, including improved oxygen delivery, faster recovery, and sustained power output, are now addressed through legal, monitored, and evidence-based clinical tools in appropriate patient populations.

Iron and Hematopoietic Optimization

Iron deficiency anemia is common and treatable. Oral iron supplementation at 150 to 200 mg elemental iron per day corrects deficiency in most patients over 8 to 12 weeks [15]. Intravenous iron (ferric carboxymaltose, brand name Injectafer) is FDA-approved for iron deficiency anemia when oral iron is insufficient or not tolerated [16]. Neither requires a WADA exemption.

Testosterone Replacement Therapy in Diagnosed Hypogonadism

Men with confirmed hypogonadism (two morning total testosterone measurements below 300 ng/dL) can benefit substantially from TRT. A 2016 randomized trial, the Testosterone Trials (TTrials, N=790, mean age 72), found that testosterone improved sexual function, physical performance, and bone density over 12 months compared with placebo [17]. The key distinction from doping is medical indication, physician supervision, and dose titration to the physiologic range.

GLP-1 Receptor Agonists and Body Composition

GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) are increasingly discussed in the context of recovery and body composition. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg subcutaneously weekly produced 14.9 percent mean body weight loss at 68 weeks versus 2.4 percent with placebo (P<0.001) [18]. These agents are FDA-approved for obesity and type 2 diabetes, and their role in athletic populations is an active area of research, not yet established practice.

Peptide Therapies: Current Evidence

Peptides such as BPC-157 and TB-500 are widely discussed in fitness communities as recovery agents. Neither has completed Phase 3 clinical trials or received FDA approval for any indication as of 2025. The FDA has issued warnings against the use of unapproved peptides compounded without adequate safety data [19]. Claims of endurance benefit for these compounds rest on preclinical animal data, not controlled human trials.

Regulatory and Disclosure Standards: What Should Change

The current regulatory environment creates an asymmetry. A pharmaceutical company must provide balanced risk information in any direct-to-consumer advertisement. A celebrity posting about a compound on a podcast or social media platform faces no equivalent requirement.

The FDA's Office of Prescription Drug Promotion monitors promotional materials from regulated entities. It does not regulate personal testimonials. Several academic and policy groups have proposed extending disclosure requirements to paid celebrity health endorsements, similar to FTC guidelines for sponsored content, but no federal rule specifically covering prescription drug testimonials by non-physician public figures exists as of this writing [11].

Endocrinologists and sports medicine physicians interviewed in the academic literature have called for standardized disclosure norms. Dr. Gary Wadler, a former member of the WADA Foundation Board, stated in a 2007 Sports Medicine publication: "The celebrity athlete's public statements about substances carry weight far disproportionate to their medical accuracy, and the absence of a correction mechanism is a genuine public health gap" [20].

The Armstrong case is instructive because the gap between public narrative and clinical reality was eventually closed, but only through a decade of investigative journalism, federal investigation, and USADA's formal process. Most celebrity Rx disclosures will never face that level of scrutiny.

What Armstrong's Case Teaches Modern Telehealth Patients

Telehealth platforms, including those prescribing TRT, GLP-1 agonists, peptides, and other hormonal therapies, operate in an environment where celebrity influence is high and patient health literacy is variable. Three clinical lessons emerge directly from the Armstrong record.

Dose Matters More Than the Compound

Testosterone at 75 mg per week titrated to a mid-normal physiologic range is not the same compound as testosterone used to push T/E ratios to multiples of the allowable limit. EPO at 20 IU/kg three times weekly under hematologic monitoring is not the same intervention as unsupervised dosing to near-polycythemic hematocrit. The compound name alone tells patients almost nothing about risk.

Context Is Not Transferable

A 30-year-old elite cyclist with a hematocrit of 40 percent operating under team physician supervision is not the same patient as a 45-year-old sedentary man self-administering compounds purchased from an offshore supplier. Celebrity health narratives almost never include the full clinical context that would allow a general patient to assess transferability.

Supervision Changes the Risk Profile Substantially

The harms documented with EPO, testosterone, and HGH in the athletic doping context arise largely from supraphysiologic dosing without monitoring. A 2019 meta-analysis of testosterone therapy in hypogonadal men (N=3,236, 58 trials) found no significant increase in cardiovascular events compared with placebo when dosing targeted the physiologic range [21]. Supervision, monitoring, and evidence-based dosing protocols are not bureaucratic formalities. They are the primary risk-reduction mechanism.